A new study has revealed that men who don't heed recommendations for prostate cancer screenings are at a significantly higher ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Share on Pinterest Skipping cancer screenings may contribute to a higher mortality rate from prostate cancer, new research suggests. jamesbenet/Getty Images Men who often miss their prostate ...

Continuing PSA screening in older men is common practice but not recommended, highlighting the need for clearer guidance.

A UK study found that using a polygenic risk score to identify men at highest genetic risk of prostate cancer significantly ...

Getty Images The American Cancer Society recommends that Black men discuss screening with their health care provider at age 45; the Prostate Cancer Foundation recommends prostate-specific antigen ...

Distant-Stage Prostate Cancer Rising Throughout California, Mortality Rates Plateau New research shows distant-stage prostate cancer increased 6.7% annually across California between 2011 and 2021 ...

Thousands of men with prostate cancer are being left at increased risk of early death due to a scandalous postcode lottery. To maximise survival chances, the NHS should diagnose the disease and ...

leading to a 45% higher risk of death from prostate cancer compared to those who did attend their screenings. The findings were presented at the European Association of Urology Congress 2025 ...

Prostate cancer is the most common cancer among men and the second-leading cause of cancer deaths, according to UC San Francisco (UCSF). But if screening programs are introduced on a national ...